7:00 PM
 | 
Feb 07, 2013
 |  BC Extra  |  Clinical News

Avastin meets Phase III endpoint in cervical cancer

NIH's National Cancer Institute (NCI) said Genentech Inc.'s Avastin bevacizumab plus paclitaxel and either cisplatin or topotecan met the primary endpoint of improving median overall survival (OS) vs. paclitaxel and either cisplatin or topotecan alone in...

Read the full 167 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >